Leading the way in corneal therapy

Claris works to improve lives by uniting unmet needs in ophthalmology with robust science and data-driven decision making

the SCOPE

Claris is pioneering solutions for patient populations struggling with sight-threatening corneal diseases

An Estimated

12,500,000

people are affected by corneal diseases worldwide1

Corneal therapy

THE OBJECTIVE

Claris is synonymous with robust science and data-driven decision making. Our goal: Improving the lives of patients with corneal disease. Claris is developing recombinant human deleted hepatocyte growth factor (dHGF) to accelerate and improve the quality of corneal healing.

Patients first

Patient-Focused Products

  • Validated unmet medical needs
  • Novel mechanisms of action
  • Patient-friendly dosing, storage, and handling
Transformative

Breakthrough Therapy

  • Accelerate healing following injury
  • Reduce scarring in mechanical and bacterial injury models
  • Reverse recent and long-term scarring induced by injury model
  • Improve visual outcomes
Scientific rigor

Rigorous Scientific Rationale

  • Epitheliotropic
  • Anti-fibrotic
  • Neurotrophic
  • Anti-inflammatory